| Autor: |
Wang B; National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, No.1111 Halei Road, Shanghai, 201203, China. echo_bing9501@163.com., Yang L; National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, No.1111 Halei Road, Shanghai, 201203, China., Wang B; National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, No.1111 Halei Road, Shanghai, 201203, China., Luo C; National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, No.1111 Halei Road, Shanghai, 201203, China., Wang Y; Department of Chemistry, Fudan University, Shanghai, China., Wang H; National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, No.1111 Halei Road, Shanghai, 201203, China., Chen F; National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, No.1111 Halei Road, Shanghai, 201203, China., Xiang X; Department of Clinical Pharmacy, School of Pharmacy, Fudan University, No.826 Zhangheng Road, Shanghai, 201203, China. xiangxq@fudan.edu.cn. |
| Abstrakt: |
The present study endeavored to develop orodispersible films (ODFs) containing 30 mg racecadotril for pediatric use, which focuses on improving the compliance of pediatric patients and reducing risk of choking. The challenge of this study is to prepare high drug loading ODFs with successful mechanical and physicochemical properties. Compatibilities between drug and different polymers (hydroxypropyl methylcellulose, HPMC; polyvinyl alcohol, PVA; low-substituted hydroxypropyl cellulose, L-HPC; pullulan, PU) were investigated to select stable and safe film-forming polymers. Afterwards, the study explored the maximum amount of racecadotril incorporated into PVA films and PU films. Subsequently, disintegrant (Lycoat RS720, 4-10%, w/w) and plasticizers (glycerol, 2-6%, w/w) were investigated to reduce disintegration time of PVA films and enhance the flexibility of PU films, respectively. Formulation characteristics (appearance, tensile strength, percent elongation, disintegration time, drug content, weight, thickness, pH value, moisture content, moisture uptake, and Q 5min ) of prepared ODFs were examined to obtain the optimal compositions of racecadotril ODFs. Differential scanning calorimetry (DSC) study, powder X-ray diffraction (XRD) study, Fourier transform infrared (FTIR) study, comparative in vitro dissolution study, and pharmacokinetic study in Beagle dogs of optimized racecadotril ODFs were then conducted. Eventually, ODFs containing 50% racecadotril, 38% PVA, 7% Lycoat RS720, 2% sucralose, 2% apricot, and 1% titanium dioxide could achieve desirable mechanical properties, disintegrating within a few seconds and releasing more than 85% drug within 5 min in four dissolution media. An in vivo study showed optimized racecadotril ODF and Hidrasec were bioequivalent in Beagle dogs. In summary, ODFs containing 30 mg racecadotril were successfully prepared by solvent casting method, and it was suitable for the administration to the pediatric patients. |
Full text from SpringerLink